What does Glean® Urodynamics System cost?

A new wireless urodynamics platform with pricing still under development—updated pricing intel coming as quotes accrue.

The Glean Urodynamics System is too new to have public pricing. The device received FDA 510(k) clearance in March 2025 , and commercial deployment is in early stages. Manufacturer list prices have not been released. This article will be updated as hospital procurement data, GPO pricing, and vendor quotes become available. Procurement officers should expect pricing inquiries to Bright Uro (manufacturer, Irvine, CA) to yield custom quotes based on system configuration and service tier.

Device specifications: what you're pricing

The Glean system is a single-use-sensor, reusable-console platform designed to replace conventional catheter-based urodynamics:

• Core components: Three physical components—the Sensor, Insertion Tool, and Uroflowmeter—and three software applications: the Glean Mobile App for Clinicians, the Glean Mobile App for Patients, and the Glean Web App

• Modularity: Male and female delivery systems (GUS-1000-M, GUS-1000-F) with separate uroflowmeter (UFM-1000)

• Clinical scope: Performs Uroflow, Cystometrogram (CMG), Urethral Pressure Profile (UPP) and Micturition Studies

• Data flow: Components communicate wirelessly via Bluetooth and cloud connectivity to provide cystometrogram, urethral pressure profile, and pressure flow data without a catheter

Context: conventional urodynamics cost baseline

To frame Glean pricing, understand the incumbent market. Average cost of urodynamic system medical devices is currently $2,648 (used/aggregate market); this represents smaller, older systems. Full-featured conventional systems run higher. Medicare reimbursement for minimum complex cystometrogram plus uroflow testing ranged from $350 to $375 per study , indicating per-test service cost, not capital equipment cost. Consumable costs for traditional catheters, transducers, and electrodes remain significant— competitor catheter prices increased 153% over six years, raising average per-study cost from $90.66 to $208.28 .

The Glean system uses a single disposable sensor per patient study, which may reduce or redistribute consumable spend.

What will likely push Glean pricing

Capital cost drivers:

• Reusable console & software stack: Bluetooth wireless receiver, clinician app, patient app, and cloud portal hosting carry development cost. Bright Uro's pricing model will reflect SaaS-like recurring revenue (cloud storage, data management, multi-clinic licensing).
• Portability premium: The device's practical advantages include low capital cost, portability, and minimal training requirements, enabling urodynamics to be performed across more clinic locations and reduce wait times . Vendors often charge a mobility/flexibility premium.
• Clinical adoption stage: As a March 2025 FDA clearance, Glean is in market penetration phase. Early pricing is often higher than mature products as manufacturers build market share.

Consumable cost drivers:

• Sensor cost per test: No published price for the disposable sensor. Expect this to be the dominant per-study cost.
• Gender-specific sensors: Separate male and female delivery systems may require inventory duplication.
• Optional abdominal pressure sensor: An optional abdominal pressure sensor is planned for insertion into the rectum, available in 2026 —likely an upsell.

What will likely push Glean pricing down

Market dynamics:

• Reduced operator training: 81% of Glean sensor insertions were rated as easy or very easy by clinicians , reducing the need for specialist staff. Lower labor overhead may translate to lower licensing costs than conventional urodynamics.
• Multi-location deployment: Clinicians report ideal use in practices with multiple offices that previously shared 1–2 conventional machines . One Glean system can support many sites, lowering per-location capex.
• Volume adoption & competition: Bright Uro is the only player in wireless catheter-free urodynamics. Once pricing is public and adoption accelerates, GPO contracts and volume discounts will emerge.

Hidden costs and dependencies

• Cloud infrastructure & SaaS licensing: Data synchronization requires ongoing internet connectivity. Expect annual hosting/licensing fees.
• Training & onboarding: Minimal but non-zero. Budget for staff certifications.
• Sensor inventory: Disposable sensors must be stocked. Bulk ordering discounts may apply.
• Mobile device requirements: Clinician and patient apps require iOS/Android devices (tablets/phones). Existing IT may suffice, but integration should be confirmed.
• Integration with EMR: Cloud sync capability will require network validation and potential IT support.
• Regulatory updates: As a Class II device, firmware/software updates may require re-validation.

Negotiation tactics for early adopters

1. Request pilot pricing: Manufacturers often discount pilot programs. Propose a 3–6 month evaluation with 5–10 patient studies to justify volume commitments.
2. Bundle sensor contracts: Negotiate annual sensor volume discounts tied to study throughput. Clarify storage/expiration terms.
3. Multi-location licensing: If deploying across sites, request per-site or per-clinician licensing discounts, not per-device fees.
4. Service level agreements: Request defined response times for technical support, especially for cloud/app issues.
5. Competitive intel: Conventional urodynamics vendors (e.g., Laborie, SRS Medical) may lower pricing when threatened by Glean adoption. Request re-bids.
6. GPO eligibility: Confirm whether Bright Uro will enroll in established GPOs (Premier, MedAssets, etc.) to unlock group discounts.

Red flags when pricing emerges

• Sensor costs exceed $500 per test: Consumables should be competitive with catheter costs (~$200–300 range) for ROI to materialize.
• Cloud SaaS fees >$200/month: Data hosting for a small clinic should not rival enterprise costs.
• Required "premium training" at >$5K per site: Training overhead should not exceed 10% of system cost.
• Proprietary mobile devices required: Reject bundled tablet/phone offerings; insist on BYOD (bring your own device) compatibility.
• No multi-year warranty: Early-stage devices should carry 3+ years parts/labor coverage to offset adoption risk.

Sources

FDA 510(k) submission K243052 (Bright Uro, March 24, 2025): Glean Urodynamics System specifications and intended use

Journal of Endourology (2025): "The Feasibility and Safety of the Glean Urodynamics System: The Modern Urodynamics System Efficacy Study" (MUSE trial results)

Grand Rounds in Urology presentation (September 2025): Dr. Scott MacDiarmid on cost and deployment advantages

Gemini Med Tech market analysis (February 2025): Conventional urodynamic consumable inflation trends

---

Note to MedSource readers: This article will be updated with verified pricing as soon as quotes, GPO contracts, or manufacturer list prices become available. If you have current pricing intel, please contact MedSource procurement research.